NO20091598L - P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav - Google Patents

P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav

Info

Publication number: NO20091598L
Authority: NO; Norway
Prior art keywords: ribofuranosyl; deoxy; acetyl; amino; preparation
Prior art date: 2006-10-17

Application number

NO20091598A

Other languages

English (en)

Norwegian (no)

Inventor

David J Kucera

Tingmin Wang

Gregory J Haley

Erik J Rueden

Fritz Blatter

Martin Viertelhaus

Original Assignee

Anadys Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-17

Filing date

2009-04-22

Publication date

2009-07-10

2009-04-22 Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc

2009-07-10 Publication of NO20091598L publication Critical patent/NO20091598L/no

Links

JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
208000036142 Viral infection Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
-1 furanose compounds Chemical class 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20091598A 2006-10-17 2009-04-22 P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav NO20091598L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US85200206P	2006-10-17	2006-10-17
US89940507P	2007-02-05	2007-02-05
US95359707P	2007-08-02	2007-08-02
PCT/US2007/081526 WO2008140549A1 (en)	2006-10-17	2007-10-16	P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION

Publications (1)

Publication Number	Publication Date
NO20091598L true NO20091598L (no)	2009-07-10

Family

ID=39472747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091598A NO20091598L (no)	2006-10-17	2009-04-22	P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav

Country Status (24)

Country	Link
US (2)	US7928085B2 (pl)
EP (1)	EP2076132B1 (pl)
JP (2)	JP5279715B2 (pl)
KR (2)	KR101515077B1 (pl)
AR (1)	AR063484A1 (pl)
AU (1)	AU2007353381B2 (pl)
BR (1)	BRPI0717741A2 (pl)
CA (2)	CA2666537C (pl)
CY (1)	CY1113368T1 (pl)
DK (1)	DK2076132T3 (pl)
DO (1)	DOP2007000131A (pl)
EA (1)	EA017005B1 (pl)
ES (1)	ES2390930T3 (pl)
IL (2)	IL198180A (pl)
MX (1)	MX2009004028A (pl)
MY (1)	MY150408A (pl)
NO (1)	NO20091598L (pl)
NZ (1)	NZ576408A (pl)
PE (1)	PE20081105A1 (pl)
PL (1)	PL2076132T3 (pl)
PT (1)	PT2076132E (pl)
TW (1)	TWI415854B (pl)
UY (1)	UY30650A1 (pl)
WO (1)	WO2008140549A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101461604B1 (ko)	2006-06-22	2014-11-18	애나디스 파마슈티칼스, 인코포레이티드	5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
WO2009026292A1 (en)	2007-08-20	2009-02-26	Anadys Pharmaceuticals, Inc.	Dosing methods for treating disease
SG11201704512PA (en)	2014-12-08	2017-07-28	Hoffmann La Roche	3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
US9676793B2 (en)	2014-12-23	2017-06-13	Hoffmann-Laroche Inc.	Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CA2979490C (en)	2015-03-16	2023-07-18	F. Hoffmann-La Roche Ag	Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN107743491B (zh)	2015-05-08	2020-08-21	豪夫迈·罗氏有限公司	用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP6806709B2 (ja)	2015-05-12	2021-01-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
WO2017001307A1 (en)	2015-06-30	2017-01-05	F. Hoffmann-La Roche Ag	Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
CA3048768A1 (en)	2017-01-06	2018-07-12	F. Hoffmann-La Roche Ag	Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN110007010A (zh) *	2018-01-05	2019-07-12	大鹏药品工业株式会社	源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07224081A (ja) *	1994-02-10	1995-08-22	Kobayashi Koryo Kk	デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) *	1995-06-06	1996-07-02	Hitachi Chemical Company, Ltd.	Method of preparation of bis-quinolines
JP4067226B2 (ja) *	1999-04-01	2008-03-26	三井化学株式会社	１―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) *	1999-05-21	2000-11-28	Mitsui Chemicals Inc	２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) *	2001-05-30	2003-11-18	Merck & Co., Inc.	Process for preparing piperazinepentaneamide HIV protease inhibitors
AP2004003069A0 (en) *	2001-11-27	2004-06-30	Anadys Pharmaceuticals Inc	3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
AU2003289995A1 (en) *	2002-12-09	2004-06-30	Texcontor Etablissement	Anhydrous crystalline form of valacyclovir hydrochloride
JP2007504232A (ja) *	2003-09-05	2007-03-01	アナディスファーマシューティカルズインク	Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
CA2566541C (en) *	2004-06-07	2012-10-09	Anadys Pharmaceuticals, Inc.	3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
US7560544B2 (en) *	2004-12-17	2009-07-14	Anadys Pharmaceuticals, Inc.	3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US7501526B2 (en) *	2005-01-20	2009-03-10	Taigen Biotechnology	Synthesis of polyamine compounds
KR101461604B1 (ko) *	2006-06-22	2014-11-18	애나디스 파마슈티칼스, 인코포레이티드	5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
KR101266843B1 (ko) *	2006-12-08	2013-05-24	가부시키가이샤 에이피아이 코포레이션	퓨라노스 유도체의 제조방법

2007
- 2007-10-06 BR BRPI0717741-0A2A patent/BRPI0717741A2/pt not_active Application Discontinuation
- 2007-10-16 EA EA200970387A patent/EA017005B1/ru not_active IP Right Cessation
- 2007-10-16 MY MYPI20091559 patent/MY150408A/en unknown
- 2007-10-16 NZ NZ576408A patent/NZ576408A/en not_active IP Right Cessation
- 2007-10-16 PE PE2007001399A patent/PE20081105A1/es not_active Application Discontinuation
- 2007-10-16 CA CA2666537A patent/CA2666537C/en not_active Expired - Fee Related
- 2007-10-16 ES ES07873546T patent/ES2390930T3/es active Active
- 2007-10-16 DK DK07873546.1T patent/DK2076132T3/da active
- 2007-10-16 TW TW096138583A patent/TWI415854B/zh not_active IP Right Cessation
- 2007-10-16 PL PL07873546T patent/PL2076132T3/pl unknown
- 2007-10-16 PT PT07873546T patent/PT2076132E/pt unknown
- 2007-10-16 US US11/873,202 patent/US7928085B2/en not_active Expired - Fee Related
- 2007-10-16 WO PCT/US2007/081526 patent/WO2008140549A1/en not_active Ceased
- 2007-10-16 MX MX2009004028A patent/MX2009004028A/es active IP Right Grant
- 2007-10-16 KR KR1020147026217A patent/KR101515077B1/ko not_active Expired - Fee Related
- 2007-10-16 KR KR1020097010038A patent/KR101486444B1/ko not_active Expired - Fee Related
- 2007-10-16 AU AU2007353381A patent/AU2007353381B2/en not_active Ceased
- 2007-10-16 EP EP07873546A patent/EP2076132B1/en not_active Not-in-force
- 2007-10-16 JP JP2009533481A patent/JP5279715B2/ja not_active Expired - Fee Related
- 2007-10-16 CA CA2898225A patent/CA2898225A1/en not_active Abandoned
- 2007-10-17 UY UY30650A patent/UY30650A1/es not_active Application Discontinuation
- 2007-10-17 DO DO2007000131A patent/DOP2007000131A/es unknown
- 2007-10-17 AR ARP070104611A patent/AR063484A1/es unknown
2009
- 2009-04-16 IL IL198180A patent/IL198180A/en active IP Right Grant
- 2009-04-22 NO NO20091598A patent/NO20091598L/no not_active Application Discontinuation
2011
- 2011-03-23 US US13/069,426 patent/US8193342B2/en not_active Expired - Fee Related
2012
- 2012-09-28 CY CY20121100897T patent/CY1113368T1/el unknown
- 2012-11-19 IL IL223126A patent/IL223126A/en active IP Right Grant
2013
- 2013-05-21 JP JP2013107302A patent/JP5703334B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY150408A (en)	2014-01-15
KR101515077B1 (ko)	2015-04-24
EP2076132B1 (en)	2012-07-11
IL223126A0 (en)	2012-12-31
DOP2007000131A (es)	2008-09-15
EA200970387A1 (ru)	2009-10-30
TW200833699A (en)	2008-08-16
US20090197826A1 (en)	2009-08-06
MX2009004028A (es)	2009-05-11
BRPI0717741A2 (pt)	2014-04-08
PE20081105A1 (es)	2008-08-15
TWI415854B (zh)	2013-11-21
KR20090074237A (ko)	2009-07-06
US20110172447A1 (en)	2011-07-14
CA2898225A1 (en)	2008-11-20
PL2076132T3 (pl)	2013-01-31
JP5279715B2 (ja)	2013-09-04
US8193342B2 (en)	2012-06-05
KR20140119203A (ko)	2014-10-08
WO2008140549A1 (en)	2008-11-20
EP2076132A4 (en)	2011-05-04
NZ576408A (en)	2012-04-27
HK1132429A1 (en)	2010-02-26
AU2007353381A1 (en)	2008-11-20
PT2076132E (pt)	2012-10-03
DK2076132T3 (da)	2012-09-10
EP2076132A1 (en)	2009-07-08
IL223126A (en)	2016-08-31
AU2007353381B2 (en)	2013-07-04
KR101486444B1 (ko)	2015-01-26
JP5703334B2 (ja)	2015-04-15
AR063484A1 (es)	2009-01-28
IL198180A0 (en)	2009-12-24
CA2666537A1 (en)	2008-11-20
ES2390930T3 (es)	2012-11-19
EA017005B1 (ru)	2012-09-28
CY1113368T1 (el)	2016-06-22
UY30650A1 (es)	2008-05-31
CA2666537C (en)	2015-12-08
JP2013166782A (ja)	2013-08-29
JP2010506947A (ja)	2010-03-04
US7928085B2 (en)	2011-04-19
IL198180A (en)	2015-06-30

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20091598L (no)	2009-07-10	P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav
EP2114925A4 (en)	2010-10-20	AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
NO20055496L (no)	2006-02-14	Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
BRPI0511078A (pt)	2007-12-26	compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso
WO2004041203A3 (en)	2005-04-21	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
NZ543467A (en)	2008-07-31	The severe acute respiratory syndrome coronavirus
WO2007041130A3 (en)	2010-01-21	Deazapurines useful as inhibitors of janus kinases
BRPI0418351A (pt)	2007-05-08	composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0310106A (pt)	2005-02-22	Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20072223L (no)	2007-06-25	Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
NO20072548L (no)	2007-07-20	Xantinderivater med HM74A reseptoraktivitet
EA200701808A1 (ru)	2008-02-28	Производные тетрагидроиндолона и тетрагидроиндазолона
WO2005110994A3 (en)	2006-02-02	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
CR7043A (es)	2003-11-25	Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
NO20070782L (no)	2007-04-02	Tetrapeptidanaloger.
UA99924C2 (en)	2012-10-25	Benzylbenzol derivatives and using thereof
GEP20115283B (en)	2011-09-12	Pyrrolopyrimidine compounds and their uses
NO20055894L (no)	2006-03-21	Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20073367L (no)	2007-09-05	Makrolider
DE602004024037D1 (de)	2009-12-24	Substituierte heterozyklen
NO20075815L (no)	2008-01-11	Formuleringer og metoder for behandling av amyloidose
CL2008000021A1 (es)	2009-03-27	Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
PT1325011E (pt)	2004-09-30	Metodos e compostos para tratamento de doencas proliferativas